(Q43886123)

27 November 2017

title

Low dose ketamine as an analgesic adjuvant in difficult pain syndromes: a strategy for conversion from parenteral to oral ketamine (English)

1 reference

27 November 2017

Edward J Fitzgibbon

1

1 reference

27 November 2017

Pippa Hall

2

1 reference

27 November 2017

Cori Schroder

3

1 reference

27 November 2017

John Seely

4

1 reference

27 November 2017

Raymond Viola

5

1 reference

27 November 2017

publication date

1 February 2002

1 reference

Journal of Pain and Symptom Management

27 November 2017

published in

1 reference

27 November 2017

volume

23

1 reference

27 November 2017

issue

2

1 reference

27 November 2017

page(s)

165-170

1 reference

Continuous subcutaneous administration of the N-methyl-D-aspartic acid (NMDA) receptor antagonist ketamine in the treatment of post-herpetic neuralgia

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900393-1

7 January 2021

Relief of post-herpetic neuralgia with the N-methyl-D-aspartic acid receptor antagonist ketamine: a double-blind, cross-over comparison with morphine and placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900393-1

7 January 2021

Effective treatment of severe cancer pain of the head using low-dose ketamine in an opioid-tolerant patient

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900393-1

7 January 2021

Use and efficacy of low-dose ketamine in the management of acute postoperative pain: a review of current techniques and outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900393-1

7 January 2021

Analgesic effect of oral ketamine in chronic neuropathic pain of spinal origin: a case report.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900393-1

7 January 2021

Ketamine--its pharmacology and therapeutic uses.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900393-1

7 January 2021

Low-dose ketamine in the management of opioid nonresponsive terminal cancer pain

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900393-1

7 January 2021

Ketamine: an update on the first twenty-five years of clinical experience

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900393-1

7 January 2021

Ketamine blockage of both tetrodotoxin (TTX)-sensitive and TTX-resistant sodium channels of rat dorsal root ganglion neurons.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900393-1

7 January 2021

NMDA-receptor antagonists and opioid receptor interactions as related to analgesia and tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900393-1

7 January 2021

Update on the neurophysiology of pain transmission and modulation: focus on the NMDA-receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900393-1

7 January 2021

Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900393-1

7 January 2021

Low-dose subcutaneous ketamine infusion and morphine tolerance.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900393-1

7 January 2021

Oral administration of dextromethorphan prevents the development of morphine tolerance and dependence in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900393-1

7 January 2021

Postoperative analgesia with i.v. patient-controlled morphine: effect of adding ketamine.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900393-1

7 January 2021

Targeting the N-methyl-D-aspartate receptor for chronic pain management. Preclinical animal studies, recent clinical experience and future research directions

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900393-1

7 January 2021

Ketamine injection used orally

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900393-1

7 January 2021

Pharmacokinetics and analgesic effects of i.m. and oral ketamine

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900393-1

7 January 2021

Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900393-1

7 January 2021

Clinical experience with oral ketamine

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900393-1

7 January 2021

10.1016/S0885-3924(01)00393-1

Identifiers

DOI

1 reference

27 November 2017

1 reference